Vahid Vahedian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Vahid Vahedian has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Nouri
Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
12 shared publications Nazila Fathi Maroufi
Department of Biochemistry and Clinical Laboratories, Faculty of Medicine Tabriz University of Medical Sciences Tabriz Iran
11 shared publicationsMaryam Akbarzadeh
Department of Biochemistry, Erasmus University Medical Center, Rotterdam, The Netherlands
7 shared publicationsAlireza Isazadeh
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
6 shared publicationsYousef Faridvand
Cardiovascular Research Center Tabriz University of Medical Sciences Tabriz Iran
6 shared publicationsFarhad Pouremamali
Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
5 shared publications
Latest Publications
- 12 July 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 248, 154686
The potential therapeutic effects of Galbanic acid on cancer
- 12 July 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 248, 154686
The potential therapeutic effects of Galbanic acid on cancer
- Open Access
- 21 February 2023
- Published by Elsevier in Toxicology Reports
- Vol. 10, 436-440
Xanthomicrol: Effective therapy for cancer treatment
- 21 February 2023
- Published by Elsevier in Toxicology Reports
- Vol. 10, 436-440
Open AccessXanthomicrol: Effective therapy for cancer treatment
- Open Access
- 20 June 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 153, 113297
An evaluation on potential anti-oxidant and anti-inflammatory effects of Crocin
- 20 June 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 153, 113297
Open AccessAn evaluation on potential anti-oxidant and anti-inflammatory effects of Crocin
- 16 June 2022
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 43 (4) , 389-396
Potential tumor marker for hepatocellular carcinoma identification: PI3K and pro-inflammatory cytokines (TGF-β, IL-1, and IL-6)
Objectives: Hepatocellular carcinoma (HCC), the most common form of liver cancer, is a leading cause of tumor-associated mortality worldwide. Diagnosis based upon non-invasive criteria is currently challenged by the need for molecular information that requires tissue or liquid biopsies. The progression of HCC is often associated with chronic inflammation, expression levels of inflammatory mediators, chemokine, and cytokines. In this study, we try to evaluate the PI3K and pro-inflammatory cytokines, TGF-β, IL-1, and IL-6 expression level in patients with liver cancer. Materials and methods: The kupffer cells were isolated from patient’s specimens. Real-time PCR was applied to evaluate the expression level of PI3K in cell lines or tumors. The concentrations of TGF-β, IL-1, and IL-6 were measured by the quantitative ELISA kit. Results: PI3K mRNA expression in cancer cells was increased markedly vs. normal cells. The ELISA results demonstrated over expression of TGF-β, IL-1, and IL-6 in patients and positive correlation between tumor size and stage. Discussion: This study suggests that targeting the expression level of PI3K and pro-inflammatory chemokine and cytokines, TGF-β, IL-1, and IL-6, may be a potential diagnostic strategy in HCC patients.
- 16 June 2022
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 43 (4) , 389-396
Potential tumor marker for hepatocellular carcinoma identification: PI3K and pro-inflammatory cytokines (TGF-β, IL-1, and IL-6)
Objectives: Hepatocellular carcinoma (HCC), the most common form of liver cancer, is a leading cause of tumor-associated mortality worldwide. Diagnosis based upon non-invasive criteria is currently challenged by the need for molecular information that requires tissue or liquid biopsies. The progression of HCC is often associated with chronic inflammation, expression levels of inflammatory mediators, chemokine, and cytokines. In this study, we try to evaluate the PI3K and pro-inflammatory cytokines, TGF-β, IL-1, and IL-6 expression level in patients with liver cancer. Materials and methods: The kupffer cells were isolated from patient’s specimens. Real-time PCR was applied to evaluate the expression level of PI3K in cell lines or tumors. The concentrations of TGF-β, IL-1, and IL-6 were measured by the quantitative ELISA kit. Results: PI3K mRNA expression in cancer cells was increased markedly vs. normal cells. The ELISA results demonstrated over expression of TGF-β, IL-1, and IL-6 in patients and positive correlation between tumor size and stage. Discussion: This study suggests that targeting the expression level of PI3K and pro-inflammatory chemokine and cytokines, TGF-β, IL-1, and IL-6, may be a potential diagnostic strategy in HCC patients.
- 27 April 2022
- Published by Elsevier in Pathology - Research and Practice
- Vol. 234, 153922
Vascular mimicry: A potential therapeutic target in breast cancer
- 27 April 2022
- Published by Elsevier in Pathology - Research and Practice
- Vol. 234, 153922
Vascular mimicry: A potential therapeutic target in breast cancer
- 2 April 2022
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 49 (6) , 643-651
Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation
Hyperglycaemia is a major cause of pathophysiological processes such as oxidative stress, inflammation, and apoptosis in diabetes. Dapagliflozin (DAPA), a novel hypoglycaemic drug, has been shown to have anti‐apoptotic, anti‐inflammatory, and antioxidant effects in multiple experimental studies. In this study, we investigated the protective effects of DAPA in the hyperglycaemic condition to identify associated molecular mechanisms. human umbilical vein endothelial cells (HUVEC) endothelial cells were treated with 40 mM glucose for 72 h to establish an in vitro high glucose (HG) condition model, and then additional groups co‐treated with or without DAPA before glucose treatment. Then, cell viability, reactive oxygen species (ROS), pro‐inflammatory cytokines (IL‐6 and TNF‐α), apoptosis, and SIRT1 expression were measured. The results showed that DAPA pretreatment resulted in increased cell viability. Additionally, DAPA pretreatment decreased endothelial ROS, IL‐6, and TNF‐α levels in endothelial cells subjected to HG conditions. Moreover, DAPA pretreatment significantly prevented HG‐induced apoptosis and caspase‐3 activity in HUVECs. Furthermore, DAPA increased the expression of SIRT1, PGC‐1α, and increased the phosphorylation levels of AMPK (p‐AMPK) in a set of HG conditions in HUVECs. However, the endothelial protective effects of DAPA were abolished when cells were subjected to the SIRT1 inhibitor (EX‐527) and AMPK inhibitor (Compound C). These findings suggest that DAPA can abrogate HG‐induced endothelial cell dysfunction by AMPK/SIRT1 pathway up‐regulation. Therefore, suggesting that the activation of AMPK/SIRT1 axis by DAPA may be a novel target for the treatment of HG‐induced endothelial cell injury.
- 2 April 2022
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 49 (6) , 643-651
Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation
Hyperglycaemia is a major cause of pathophysiological processes such as oxidative stress, inflammation, and apoptosis in diabetes. Dapagliflozin (DAPA), a novel hypoglycaemic drug, has been shown to have anti‐apoptotic, anti‐inflammatory, and antioxidant effects in multiple experimental studies. In this study, we investigated the protective effects of DAPA in the hyperglycaemic condition to identify associated molecular mechanisms. human umbilical vein endothelial cells (HUVEC) endothelial cells were treated with 40 mM glucose for 72 h to establish an in vitro high glucose (HG) condition model, and then additional groups co‐treated with or without DAPA before glucose treatment. Then, cell viability, reactive oxygen species (ROS), pro‐inflammatory cytokines (IL‐6 and TNF‐α), apoptosis, and SIRT1 expression were measured. The results showed that DAPA pretreatment resulted in increased cell viability. Additionally, DAPA pretreatment decreased endothelial ROS, IL‐6, and TNF‐α levels in endothelial cells subjected to HG conditions. Moreover, DAPA pretreatment significantly prevented HG‐induced apoptosis and caspase‐3 activity in HUVECs. Furthermore, DAPA increased the expression of SIRT1, PGC‐1α, and increased the phosphorylation levels of AMPK (p‐AMPK) in a set of HG conditions in HUVECs. However, the endothelial protective effects of DAPA were abolished when cells were subjected to the SIRT1 inhibitor (EX‐527) and AMPK inhibitor (Compound C). These findings suggest that DAPA can abrogate HG‐induced endothelial cell dysfunction by AMPK/SIRT1 pathway up‐regulation. Therefore, suggesting that the activation of AMPK/SIRT1 axis by DAPA may be a novel target for the treatment of HG‐induced endothelial cell injury.
- 28 January 2022
- Published by Elsevier in Pathology - Research and Practice
- Vol. 231, 153783
The role of SOX family in cancer stem cell maintenance: With a focus on SOX2
- 28 January 2022
- Published by Elsevier in Pathology - Research and Practice
- Vol. 231, 153783
The role of SOX family in cancer stem cell maintenance: With a focus on SOX2
- 1 November 2021
- Published by Springer Nature in Breast Cancer
- Vol. 29 (2) , 260-273
Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line
Background and aim Vasculogenic mimicry (VM) is one of the most important causes of breast cancer metastasis and resistance against drugs. The cancer stem cells (CSCs) are known as essential factors for VM formation. In this study, the effects of melatonin, Apatinib, and a combination of Apatinib/melatonin on VM formation were investigated by breast CSCs from breast cancer cell line. Materials and methods The percentage of CSCs was determined in two breast cancer cell lines (MCF-7 and MDA-MB-231) by flow cytometry. The effects of Apatinib, melatonin, and a combination of Apatinib/melatonin were evaluated on proliferation and viability, migration and invasion, apoptosis, and VM formation in MDA-MB-231 cells. Moreover, expression levels of the involved proteins in cancer cell proliferation and viability, CSCs, migration and invasion, and VM formation were evaluated by real-time polymerase chain reaction (RT-PCR) and western blotting methods. Results Results of the present study showed that melatonin and Apatinib reduced survival rate of CSCs in a dose- and time-dependent manner. Apatinib, melatonin, and a combination of Apatinib/melatonin inhibited proliferation of breast CSCs (P ≤ 0.001). Formation of VM was decreased in the MDA-MB-231 cancer cell line treated with Apatinib and combination of Apatinib/melatonin. Apatinib and combination of Apatinib/melatonin reduced invasion of breast CSCs (P ≤ 0.0001). Expression of vascular endothelial VE-cadherin, ephrinA2 receptor (EPHA2), p-PI3K/phosphoinositide-3 kinase (PI3K) and phospho-AKT (p-AKT)/AKT ratios was decreased under the influence of Apatinib and a combination of Apatinib/melatonin (P ≤ 0.01). Conclusion Apatinib or a combination of Apatinib/melatonin may be used to manage patients with breast cancer. However, further studies are needed to identify anti-cancer mechanisms of melatonin and Apatinib for better management of the patients with breast cancer.
- 1 November 2021
- Published by Springer Nature in Breast Cancer
- Vol. 29 (2) , 260-273
Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line
Background and aim Vasculogenic mimicry (VM) is one of the most important causes of breast cancer metastasis and resistance against drugs. The cancer stem cells (CSCs) are known as essential factors for VM formation. In this study, the effects of melatonin, Apatinib, and a combination of Apatinib/melatonin on VM formation were investigated by breast CSCs from breast cancer cell line. Materials and methods The percentage of CSCs was determined in two breast cancer cell lines (MCF-7 and MDA-MB-231) by flow cytometry. The effects of Apatinib, melatonin, and a combination of Apatinib/melatonin were evaluated on proliferation and viability, migration and invasion, apoptosis, and VM formation in MDA-MB-231 cells. Moreover, expression levels of the involved proteins in cancer cell proliferation and viability, CSCs, migration and invasion, and VM formation were evaluated by real-time polymerase chain reaction (RT-PCR) and western blotting methods. Results Results of the present study showed that melatonin and Apatinib reduced survival rate of CSCs in a dose- and time-dependent manner. Apatinib, melatonin, and a combination of Apatinib/melatonin inhibited proliferation of breast CSCs (P ≤ 0.001). Formation of VM was decreased in the MDA-MB-231 cancer cell line treated with Apatinib and combination of Apatinib/melatonin. Apatinib and combination of Apatinib/melatonin reduced invasion of breast CSCs (P ≤ 0.0001). Expression of vascular endothelial VE-cadherin, ephrinA2 receptor (EPHA2), p-PI3K/phosphoinositide-3 kinase (PI3K) and phospho-AKT (p-AKT)/AKT ratios was decreased under the influence of Apatinib and a combination of Apatinib/melatonin (P ≤ 0.01). Conclusion Apatinib or a combination of Apatinib/melatonin may be used to manage patients with breast cancer. However, further studies are needed to identify anti-cancer mechanisms of melatonin and Apatinib for better management of the patients with breast cancer.
- 28 June 2021
- Published by Springer Nature in Biochemical Genetics
- Vol. 60 (1) , 1-23
Potential Therapeutic Effects of Melatonin Mediate via miRNAs in Cancer
MiRNAs are evolutionarily conserved non-coding ribonucleic acids with a length of between 19 and 25 nucleotides. Because of their ability to regulate gene expression, miRNAs have an important function in the controlling of various biological processes, such as cell cycle, differentiation, proliferation, and apoptosis. Owing to the long-standing regulative potential of miRNAs in tumor-suppressive pathways, scholars have recently paid closer attention to the expression profile of miRNAs in various types of cancer. Melatonin, an indolic compound secreted from pineal gland and some peripheral tissues, has been considered as an effective anti-tumor hormone in a wide spectrum of cancers. Furthermore, it induces apoptosis, inhibits tumor metastasis and invasion, and also angiogenesis. A growing body of evidence indicates the effects of melatonin on miRNAs expression in broad spectrum of diseases, including cancer. Due to the long-term effects of the regulation of miRNAs expression, melatonin could be a promising therapeutic factor in the treatment of cancers via the regulation of miRNAs. Therefore, in this review, we will discuss the effects of melatonin on miRNAs expression in various types of cancers.
- 28 June 2021
- Published by Springer Nature in Biochemical Genetics
- Vol. 60 (1) , 1-23
Potential Therapeutic Effects of Melatonin Mediate via miRNAs in Cancer
MiRNAs are evolutionarily conserved non-coding ribonucleic acids with a length of between 19 and 25 nucleotides. Because of their ability to regulate gene expression, miRNAs have an important function in the controlling of various biological processes, such as cell cycle, differentiation, proliferation, and apoptosis. Owing to the long-standing regulative potential of miRNAs in tumor-suppressive pathways, scholars have recently paid closer attention to the expression profile of miRNAs in various types of cancer. Melatonin, an indolic compound secreted from pineal gland and some peripheral tissues, has been considered as an effective anti-tumor hormone in a wide spectrum of cancers. Furthermore, it induces apoptosis, inhibits tumor metastasis and invasion, and also angiogenesis. A growing body of evidence indicates the effects of melatonin on miRNAs expression in broad spectrum of diseases, including cancer. Due to the long-term effects of the regulation of miRNAs expression, melatonin could be a promising therapeutic factor in the treatment of cancers via the regulation of miRNAs. Therefore, in this review, we will discuss the effects of melatonin on miRNAs expression in various types of cancers.
- 1 October 2020
- Published by Elsevier in Pathology - Research and Practice
- Vol. 216 (10) , 153226
The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor
- 1 October 2020
- Published by Elsevier in Pathology - Research and Practice
- Vol. 216 (10) , 153226
The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor